How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Transcervical Tubal Sterilization Market
- By Procedure Type: Essure Procedure, Adiana Procedure, Other Non-incisional Transcervical Methods
- By Device Type: Nickel-Titanium Coil Implants, Polymer-Based Implants, Biocompatible Metal Devices
- By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics
- By Patient Demographics: Women Aged 20-34, Women Aged 35-44, Women Aged 45 and Above
- By Distribution Channel: Direct Hospital Sales, Distributor Sales, Online Medical Device Platforms
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Essure Procedure leads By Procedure Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 275 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.171 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Transcervical Tubal Sterilization Market report
A complete, evidence-based study - 12 chapters and 115 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Procedure Type 3
Device Type 3
End-User 3
Patient Demographics 3
Distribution Channel 3
Companies profiled
Hologic Inc.
Conceptus
Inc. (a subsidiary of Bayer AG)
Cook Medical
Boston Scientific Corporation
Becton
Dickinson and Company (BD)
MyoSure (Hologic)
Medi-Globe GmbH
Microbot Medical
Gynesonics Inc.
SurgiTel
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Conceptus
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Inc. (a subsidiary of Bayer AG)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cook Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →MyoSure (Hologic)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Medi-Globe GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Microbot Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Gynesonics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →SurgiTel
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,162M by 2033 · 7.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Essure Procedure75.6
- Adiana Procedure14.2
- Other Non-incisional Transcervical Methods10.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$398.4M → $685.4M · 7.0%
Europe$277.7M → $479.4M · 7.1%
Asia Pacific$253.5M → $456.2M · 7.6%
Latin America$157.0M → $285.0M · 7.7%
Middle East and Africa$120.7M → $239.8M · 9.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.502026
7.522027
7.522028
7.542029
7.562030
7.562031
7.592032
7.592033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Hologic Inc.19.0
- Conceptus12.7
- Inc. (a subsidiary of Bayer AG)10.7
- Cook Medical13.1
- Boston Scientific Corporation9.9
- Becton6.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Procedure Type19.4%
Device Type27.0%
End-User13.8%
Patient Demographics29.0%
Distribution Channel10.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe22.3
- Asia Pacific21.3
- Latin America13.3
- Middle East and Africa11.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Hologic Inc. | 79 | 98 | 94 | 88 | 82 | 99 | 90 |
| Conceptus | 78 | 70 | 75 | 69 | 78 | 77 | 75 |
| Inc. (a subsidiary of Bayer AG) | 77 | 73 | 66 | 86 | 64 | 83 | 75 |
| Cook Medical | 73 | 63 | 63 | 77 | 74 | 73 | 71 |
| Boston Scientific Corporation | 53 | 68 | 61 | 53 | 73 | 71 | 63 |
| Becton | 55 | 53 | 69 | 59 | 58 | 50 | 57 |
| Dickinson and Company (BD) | 52 | 45 | 47 | 63 | 57 | 53 | 53 |
| MyoSure (Hologic) | 50 | 48 | 36 | 60 | 53 | 49 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Hologic Inc.
- Conceptus
- Inc. (a subsidiary of Bayer AG)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Hologic Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Conceptus | ◐ | ◐ | ◐ | − | ✓ | ◐ |
| Inc. (a subsidiary of Bayer AG) | ◐ | ◐ | ◐ | ✓ | − | ✓ |
| Cook Medical | ◐ | ◐ | − | ✓ | ◐ | − |
| Boston Scientific Corporation | ◐ | ◐ | ◐ | − | ✓ | ◐ |
| Becton | − | ◐ | ◐ | ◐ | − | ◐ |
| Dickinson and Company (BD) | − | − | − | ◐ | − | ◐ |
| MyoSure (Hologic) | ◐ | − | − | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Hologic Inc.90
2Conceptus75
3Inc. (a subsidiary of Bayer AG)75
4Cook Medical71
5Boston Scientific Corporation63
6Becton57
7Dickinson and Company (BD)53
8MyoSure (Hologic)49
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Hologic Inc.
Challenger3
Strong scale, closing on the leaders.
ConceptusInc. (a subsidiary of Bayer AG)Cook Medical
Contender2
Focused players with pockets of strength.
Boston Scientific CorporationBecton
Niche2
Specialists in a single segment or region.
Dickinson and Company (BD)MyoSure (Hologic)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Procedure Type in North America, then scale across Transcervical Tubal Sterilization Market — a $414M beachhead inside a $6.85B market.
Beachhead (SOM)$414Mobtainable near-term
Serviceable (SAM)$2.45Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Essure Procedure
Best fit — highest urgency & budget in Procedure Type.
Economic buyer75 fit
Adiana Procedure
Strong fit — clear ROI and a fast path to value.
End user66 fit
Other Non-incisional Transcervical Methods
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Procedure Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Device Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Procedure Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Transcervical Tubal Sterilization Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified26%
Evaluation12%
Closed-won7%
$15.1KCAC
$87KLTV
5.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Transcervical Tubal Sterilization Market is a durable-growth opportunity — $3.25B by 2033, compounding at 9.6%.
TAM · 2025$1.56Btoday
TAM · 2033$3.25Bforecast
CAGR9.6%2027–2033
Cumulative$20.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.25BTotal addressable market
SAM$1.12BServiceable available market
SOM$220MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.6% CAGR
Demand compounds through 2033, outpacing GDP across Procedure Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Procedure Type moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.25BLarge & growingTAM by 2033 at 9.6% CAGR
$1.12BServiceable nowreachable with today’s model
$220MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.53BBear6.3% CAGR
$3.25BBase9.6% CAGR
$4.16BBull12.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Device Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Transcervical Tubal Sterilization Market — a $1.05B market by 2033. Plan: grow share from 9.2% to 18.9%.
Market size · 2033$1.05Btotal addressable
Market CAGR6.8%2027–2033
Target share18.9%from 9.2% today
Revenue ambition$199Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.2% | 18.9% | Behind |
| Revenue | $96M | $199M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 37.2% | 38.9% | On track |
| Customer retention | 85.2% | 93.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Procedure Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Device Type capability
A defensible second engine — invest in Device Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Procedure Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Device Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $26M capacity & capability investment
- Greenlight bolt-on M&A in Device Type
- Authorise North America expansion plan
- Fund R&D program for Procedure Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Transcervical Tubal Sterilization Market conversation — a $10.0B market you can size, segment and defend in minutes.
Market size · 2033$10.0Btotal opportunity
Growth11.2%CAGR to 2033
Addressable buyers921+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Procedure Type
Goal Grow share in Procedure Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 3 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Hologic Inc.ConceptusInc. (a subsidiary of Bayer AG)Cook MedicalBoston Scientific CorporationBectonDickinson and Company (BD)MyoSure (Hologic)+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Transcervical Tubal Sterilization Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Transcervical Tubal Sterilization Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Ulcerative Colitis Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportWavefront Aberrometers Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportElectrolyte Tablet Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportElectrolyte Supplement Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportElectrolytes Testing Reagents Test Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportElectrolyte Ion analyzer Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportPharmaceutical Desiccant Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportBromo Trifluoro Propene Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportBiochemical Sensors Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportElectrolyte Capsules Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportChitin and Chitosan Derivatives Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportChiral Technology Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.